CEL-SCI Advances Multikine Toward Registration with 212-Patient Confirmatory Study for Head and Neck Cancer
核心洞察
CEL-SCI received FDA approval to proceed with a 212-patient confirmatory registration study for Multikine in PD-L1 (搜索) low head and neck cancer patients, with enrollment expected to begin in Spring 2026.
The company filed for Breakthrough Medicine Designation for Multikine in Saudi Arabia and completed manufacturing preparations at its cGMP facility for the upcoming registration trial.
Previous Phase 3 data showed Multikine achieved 73% long-term survival versus 45% without treatment, with a 66% reduction in death risk for patients with low to zero PD-L1 (搜索) expression.
CEL-SCI Corporation has received FDA clearance to advance its immunotherapy candidate Multikine into a pivotal 212-patient confirmatory registration study for newly diagnosed head and neck cancer patients with low PD-L1 (搜索) expression. The company announced enrollment is expected to begin in Spring 2026, marking a critical milestone toward potential regulatory approval.
Confirmatory Registration Study Design
The FDA-approved confirmatory registration study will focus specifically on patients who demonstrated the strongest responses in CEL-SCI's completed Phase 3 trial. According to CEO Geert Kersten, "The Confirmatory Registration study required by the FDA is designed to confirm data from our prior Phase 3 study by evaluating Multikine in only those patients who showed the best type of tumor responses and survival in that study in a highly statistically significant manner."
The study will enroll newly diagnosed locally advanced resectable head and neck cancer patients with no lymph node involvement, as determined by PET scan, and with low PD-L1 (搜索) tumor expression confirmed by biopsy. This patient population represents approximately 100,000 patients annually in the United States.
Strong Phase 3 Survival Data
The confirmatory study builds on compelling survival data from CEL-SCI's completed 928-patient randomized controlled Phase 3 trial. In the target population of patients with low to zero PD-L1 (搜索) levels, Multikine demonstrated 73% long-term survival compared to 45% without the drug. The therapy reduced the risk of death by 66% compared to standard of care in this patient subset.
These results contrast with existing PD-L1 (搜索) targeted therapies. While Merck (搜索)'s Keytruda, approved by the FDA in June 2025 for head and neck cancer patients with high PD-L1 expression, reduced the risk of recurrence and progression by 30% without demonstrating overall survival improvement, Multikine specifically targets the complementary patient population with low PD-L1 expression.
International Regulatory Progress
CEL-SCI has submitted an application for Breakthrough Medicine Designation for Multikine in Saudi Arabia, working in partnership with a Saudi company as recommended by the Saudi Food and Drug Authority (SFDA). The company believes it has addressed all scientific questions posed by the SFDA and has submitted a strategic blueprint supporting Saudi Arabia's Vision 2030 biotechnology leadership goals.
Should Multikine receive regulatory clearance in Saudi Arabia, CEL-SCI is prepared to manufacture and ship doses from its U.S. facility while exploring geographic manufacturing diversification with Saudi partners.
Manufacturing and Clinical Operations
The company has completed validation of its cGMP state-of-the-art manufacturing facility and finished producing Multikine for the confirmatory registration study. CEL-SCI continues its decade-long partnership with Ergomed, a clinical research organization that was instrumental in completing the Phase 3 study and will support the final registration trial preparations.
Early Approval Strategy
CEL-SCI plans to seek early U.S. approval based on pre-surgical tumor response data, with results expected by 2028. This approach is supported by a recent third-party study published in Cancer Cell titled "Distinct CD8+ T cell (搜索) dynamics associate with response to neoadjuvant cancer immunotherapies," which validates the concept that tumor responses predict survival in neoadjuvant immunotherapy treatment of head and neck cancer.
Financial Position
For fiscal year 2025 ended September 30, CEL-SCI reported research and development expenses of $15.9 million, a 13% decrease from the previous year. The company raised gross proceeds of approximately $28.3 million through common stock sales during fiscal 2025, with operating cash expenditures of approximately $17.1 million.
Multikine (Leukocyte Interleukin, Injection) has received Orphan Drug designation from the FDA for neoadjuvant therapy in head and neck squamous cell carcinoma and has been dosed in over 740 patients across clinical trials. The therapy is designed to boost the immune system's ability to target tumors before surgery, radiation, and chemotherapy when the immune system remains relatively intact.